MIP-3 beta acts as a chemoattractant for T and B lymphocytes, dendritic cells, NK cells and myeloid progenitor cells, through specific binding to CCR7, a G-protein coupled receptor known to be up-regulated by Epstein-Barr virus infected B cells and Herpes virus infected T cells. A correlation between the response to MIP-3 beta and the level of CCR7 expression and has been revealed in the maturation of dendritic cells (DCs), and increased levels of both MIP-3 beta and CCR7 expression have been shown in bronchoalveolar lavage fluid (BALF) and BALF cells from patients with the granulomatous disorder sarcoidosis, associated predominantly with CD4+ T lymphocyte alveolitis, and hence T cell recruitment. Applications: Suitable for use in FLISA, Functional Assays, and Western Blot. Other applications not tested. Recommended Dilution: FLISA: 0.5ug/ml Western Blot: 0.1-0.2ug/ml Functional Assays: 2.7-4ug/ml Optimal dilutions to be determined by the researcher. Storage and Stability: Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile ddH2O or PBS. Aliquot to avoid repeated freezing and thawing. Store at -20C. Reconstituted product is stable for 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. Note: Applications are based on unconjugated antibody.
Reinheit:
Purified by immunoaffinity chromatography.
Formulierung:
Supplied as a liquid in PBS, pH 7.2. Labeled with Fluorescein isothiocyanate (FITC).
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
